This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ji, B.
Right arrow Articles by Grosset, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ji, B.
Right arrow Articles by Grosset, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 1998, p. 2066-2069, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro and In Vivo Activities of Moxifloxacin and Clinafloxacin against Mycobacterium tuberculosis

Baohong Ji, Nacer Lounis, Caroline Maslo, Chantal Truffot-Pernot, Pascale Bonnafous, and Jacques Grosset*

Bactériologie et Hygiène, Faculté de Médecine Pitié-Salpêtrière, Paris, France

Received 12 March 1998/Returned for modification 20 April 1998/Accepted 8 June 1998

On 10% oleic acid-albumin-dextrose-catalase-enriched 7H11 agar medium, the MIC at which 90% of the isolates are inhibited for 20 strains of Mycobacterium tuberculosis was 0.5 µg of sparfloxacin (SPFX) or moxifloxacin (MXFX) per ml and 1.0 µg of clinafloxacin (CNFX) per ml, indicating that the in vitro activities of SPFX and MXFX were virtually identical and were slightly greater than that of CNFX. However, the in vivo activities of these drugs in a murine tuberculosis model differed considerably. Female Swiss mice were infected intravenously with 6.2 × 106 CFU of the H37Rv strain and treated for 4 weeks, beginning the next day after infection, with isoniazid (INH) serving as the positive control. By the criteria of 30-day survival rate, spleen weight, gross lung lesion, and mean number of CFU in the spleen, treatment with CNFX at up to 100 mg/kg of body weight six times weekly displayed no measurable effect against M. tuberculosis, whereas both SPFX and MXFX were effective; administration six times weekly of either of the latter two drugs demonstrated dosage-dependent bactericidal effects, as measured by enumeration of CFU in the spleens, and MXFX appeared more bactericidal than the same dosage of SPFX. Of the three fluoroquinolones, only MXFX at 100 mg/kg six times weekly appeared as bactericidal as INH at 25 mg/kg six times weekly. Thus, MXFX may be an important component of the newer combined regimens for treatment of tuberculosis.

* Corresponding author. Mailing address: Bactériologie et Hygiène, Faculté de Médecine Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris Cedex 13, France. Phone: (331) 40 77 97 40. Fax: (331) 45 82 75 77. E-mail: bacterio{at}biomath.jussieu.fr.

Antimicrobial Agents and Chemotherapy, August 1998, p. 2066-2069, Vol. 42, No. 8
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Dorman, S. E., Johnson, J. L., Goldberg, S., Muzanye, G., Padayatchi, N., Bozeman, L., Heilig, C. M., Bernardo, J., Choudhri, S., Grosset, J. H., Guy, E., Guyadeen, P., Leus, M. C., Maltas, G., Menzies, D., Nuermberger, E. L., Villarino, M., Vernon, A., Chaisson, R. E., the Tuberculosis Trials Consortium, (2009). Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 180: 273-280 [Abstract] [Full Text]  
  • van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., Aarnoutse, R. E. (2009). New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development. Antimicrob. Agents Chemother. 53: 849-862 [Full Text]  
  • Dooley, K., Flexner, C., Hackman, J., Peloquin, C. A., Nuermberger, E., Chaisson, R. E., Dorman, S. E. (2008). Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations. Antimicrob. Agents Chemother. 52: 4037-4042 [Abstract] [Full Text]  
  • Pardillo, F. E. F., Burgos, J., Fajardo, T. T., Cruz, E. D., Abalos, R. M., Paredes, R. M. D., Andaya, C. E. S., Gelber, R. H. (2008). Powerful Bactericidal Activity of Moxifloxacin in Human Leprosy. Antimicrob. Agents Chemother. 52: 3113-3117 [Abstract] [Full Text]  
  • Cynamon, M., Sklaney, M. R., Shoen, C. (2007). Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J Antimicrob Chemother 60: 429-432 [Abstract] [Full Text]  
  • Nikonenko, B. V., Protopopova, M., Samala, R., Einck, L., Nacy, C. A. (2007). Drug Therapy of Experimental Tuberculosis (TB): Improved Outcome by Combining SQ109, a New Diamine Antibiotic, with Existing TB Drugs. Antimicrob. Agents Chemother. 51: 1563-1565 [Abstract] [Full Text]  
  • Matrat, S., Veziris, N., Mayer, C., Jarlier, V., Truffot-Pernot, C., Camuset, J., Bouvet, E., Cambau, E., Aubry, A. (2006). Functional Analysis of DNA Gyrase Mutant Enzymes Carrying Mutations at Position 88 in the A Subunit Found in Clinical Strains of Mycobacterium tuberculosis Resistant to Fluoroquinolones. Antimicrob. Agents Chemother. 50: 4170-4173 [Abstract] [Full Text]  
  • Lounis, N., Veziris, N., Chauffour, A., Truffot-Pernot, C., Andries, K., Jarlier, V. (2006). Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment Duration. Antimicrob. Agents Chemother. 50: 3543-3547 [Abstract] [Full Text]  
  • Ji, B., Lefrancois, S., Robert, J., Chauffour, A., Truffot, C., Jarlier, V. (2006). In Vitro and In Vivo Activities of Rifampin, Streptomycin, Amikacin, Moxifloxacin, R207910, Linezolid, and PA-824 against Mycobacterium ulcerans.. Antimicrob. Agents Chemother. 50: 1921-1926 [Abstract] [Full Text]  
  • Aubry, A., Veziris, N., Cambau, E., Truffot-Pernot, C., Jarlier, V., Fisher, L. M. (2006). Novel Gyrase Mutations in Quinolone-Resistant and -Hypersusceptible Clinical Isolates of Mycobacterium tuberculosis: Functional Analysis of Mutant Enzymes. Antimicrob. Agents Chemother. 50: 104-112 [Abstract] [Full Text]  
  • Huang, T.-S., Kunin, C. M., Shin-Jung Lee, S., Chen, Y.-S., Tu, H.-Z., Liu, Y.-C. (2005). Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. J Antimicrob Chemother 56: 1058-1062 [Abstract] [Full Text]  
  • Nuermberger, E., Tyagi, S., Williams, K. N., Rosenthal, I., Bishai, W. R., Grosset, J. H. (2005). Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model. Am. J. Respir. Crit. Care Med. 172: 1452-1456 [Abstract] [Full Text]  
  • Veziris, N., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V. (2005). Efficient Intermittent Rifapentine-Moxifloxacin-Containing Short-Course Regimen for Treatment of Tuberculosis in Mice. Antimicrob. Agents Chemother. 49: 4015-4019 [Abstract] [Full Text]  
  • Gillespie, S. H., Basu, S., Dickens, A. L., O'Sullivan, D. M., McHugh, T. D. (2005). Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 56: 344-348 [Abstract] [Full Text]  
  • Hegde, S. S., Vetting, M. W., Roderick, S. L., Mitchenall, L. A., Maxwell, A., Takiff, H. E., Blanchard, J. S. (2005). A Fluoroquinolone Resistance Protein from Mycobacterium tuberculosis That Mimics DNA. Science 308: 1480-1483 [Abstract] [Full Text]  
  • Steward, J., Piercy, T., Lever, M. S., Nelson, M., Simpson, A. J. H., Brooks, T. J. G. (2005). Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection. J Antimicrob Chemother 55: 523-527 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., Williams, K., Rosenthal, I., O'Brien, R. J., Vernon, A. A., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 170: 1131-1134 [Abstract] [Full Text]  
  • Bermudez, L. E., Kolonoski, P., Seitz, L. E., Petrofsky, M., Reynolds, R., Wu, M., Young, L. S. (2004). SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease. Antimicrob. Agents Chemother. 48: 3556-3558 [Abstract] [Full Text]  
  • Gosling, R., Gillespie, S., Pletz, M. W. R., Lode, H. (2004). Moxifloxacin Treatment of Tuberculosis. Antimicrob. Agents Chemother. 48: 3642-3643 [Full Text]  
  • Di Perri, G., Bonora, S. (2004). Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?. J Antimicrob Chemother 54: 593-602 [Abstract] [Full Text]  
  • Steward, J., Lever, M. S., Simpson, A. J. H., Sefton, A. M., Brooks, T. J. G. (2004). Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones. J Antimicrob Chemother 54: 95-99 [Abstract] [Full Text]  
  • Chan, E. D., Laurel, V., Strand, M. J., Chan, J. F., Huynh, M.-L. N., Goble, M., Iseman, M. D. (2004). Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 1103-1109 [Abstract] [Full Text]  
  • Aubry, A., Pan, X.-S., Fisher, L. M., Jarlier, V., Cambau, E. (2004). Mycobacterium tuberculosis DNA Gyrase: Interaction with Quinolones and Correlation with Antimycobacterial Drug Activity. Antimicrob. Agents Chemother. 48: 1281-1288 [Abstract] [Full Text]  
  • Shoen, C. M., DeStefano, M. S., Sklaney, M. R., Monica, B. J., Slee, A. M., Cynamon, M. H. (2004). Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. J Antimicrob Chemother 53: 641-645 [Abstract] [Full Text]  
  • Cheng, A. F. B., Yew, W. W., Chan, E. W. C., Chin, M. L., Hui, M. M. M., Chan, R. C. Y. (2004). Multiplex PCR Amplimer Conformation Analysis for Rapid Detection of gyrA Mutations in Fluoroquinolone-Resistant Mycobacterium tuberculosis Clinical Isolates. Antimicrob. Agents Chemother. 48: 596-601 [Abstract] [Full Text]  
  • Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 169: 421-426 [Abstract] [Full Text]  
  • O'Brien, R. J. (2003). Development of Fluoroquinolones as First-line Drugs for Tuberculosis--at Long Last!. Am. J. Respir. Crit. Care Med. 168: 1266-1268 [Full Text]  
  • Gosling, R. D., Uiso, L. O., Sam, N. E., Bongard, E., Kanduma, E. G., Nyindo, M., Morris, R. W., Gillespie, S. H. (2003). The Bactericidal Activity of Moxifloxacin in Patients with Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 168: 1342-1345 [Abstract] [Full Text]  
  • Veziris, N., Truffot-Pernot, C., Aubry, A., Jarlier, V., Lounis, N. (2003). Fluoroquinolone-Containing Third-Line Regimen against Mycobacterium tuberculosis In Vivo. Antimicrob. Agents Chemother. 47: 3117-3122 [Abstract] [Full Text]  
  • Hu, Y., Coates, A. R. M., Mitchison, D. A. (2003). Sterilizing Activities of Fluoroquinolones against Rifampin-Tolerant Populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47: 653-657 [Abstract] [Full Text]  
  • Lenaerts, A. J. M., Gruppo, V., Brooks, J. V., Orme, I. M. (2003). Rapid In Vivo Screening of Experimental Drugs for Tuberculosis Using Gamma Interferon Gene-Disrupted Mice. Antimicrob. Agents Chemother. 47: 783-785 [Abstract] [Full Text]  
  • Fattorini, L., Tan, D., Iona, E., Mattei, M., Giannoni, F., Brunori, L., Recchia, S., Orefici, G. (2003). Activities of Moxifloxacin Alone and in Combination with Other Antimicrobial Agents against Multidrug-Resistant Mycobacterium tuberculosis Infection in BALB/c Mice. Antimicrob. Agents Chemother. 47: 360-362 [Abstract] [Full Text]  
  • Iseman, M.D. (2002). Tuberculosis therapy: past, present and future. Eur Respir J 20: 87S-94s [Abstract] [Full Text]  
  • Yoshimatsu, T., Nuermberger, E., Tyagi, S., Chaisson, R., Bishai, W., Grosset, J. (2002). Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine Tuberculosis. Antimicrob. Agents Chemother. 46: 1875-1879 [Abstract] [Full Text]  
  • Alvirez-Freites, E. J., Carter, J. L., Cynamon, M. H. (2002). In Vitro and In Vivo Activities of Gatifloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46: 1022-1025 [Abstract] [Full Text]  
  • Piddock, L. J. V., Ricci, V. (2001). Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv. J Antimicrob Chemother 48: 787-791 [Abstract] [Full Text]  
  • Lounis, N., Bentoucha, A., Truffot-Pernot, C., Ji, B., O'Brien, R. J., Vernon, A., Roscigno, G., Grosset, J. (2001). Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice. Antimicrob. Agents Chemother. 45: 3482-3486 [Abstract] [Full Text]  
  • Lounis, N., Truffot-Pernot, C., Bentoucha, A., Robert, J., Ji, B., Grosset, J. (2001). Efficacies of Clarithromycin Regimens against Mycobacterium xenopi in Mice. Antimicrob. Agents Chemother. 45: 3229-3230 [Abstract] [Full Text]  
  • Tuberculosis Drug Screening Program, (2001). Search for New Drugs for Treatment of Tuberculosis. Antimicrob. Agents Chemother. 45: 1943-1946 [Full Text]  
  • Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., Young, L. S. (2001). Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium. Antimicrob. Agents Chemother. 45: 217-222 [Abstract] [Full Text]  
  • Aubry, A., Jarlier, V., Escolano, S., Truffot-Pernot, C., Cambau, E. (2000). Antibiotic Susceptibility Pattern of Mycobacterium marinum. Antimicrob. Agents Chemother. 44: 3133-3136 [Abstract] [Full Text]  
  • Consigny, S., Bentoucha, A., Bonnafous, P., Grosset, J., Ji, B. (2000). Bactericidal Activities of HMR 3647, Moxifloxacin, and Rifapentine against Mycobacterium leprae in Mice. Antimicrob. Agents Chemother. 44: 2919-2921 [Abstract] [Full Text]  
  • DANIEL, N., LOUNIS, N., JI, B., O'BRIEN, R. J., VERNON, A., GEITER, L. J., SZPYTMA, M., TRUFFOT-PERNOT, C., HEJBLUM, G., GROSSET, J. (2000). Antituberculosis Activity of Once-weekly Rifapentine-containing Regimens in Mice . Long-term Effectiveness with 6- and 8-Month Treatment Regimens. Am. J. Respir. Crit. Care Med. 161: 1572-1577 [Abstract] [Full Text]  
  • Miyazaki, E., Miyazaki, M., Chen, J. M., Chaisson, R. E., Bishai, W. R. (1999). Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis. Antimicrob. Agents Chemother. 43: 85-89 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»